Table 2.
Cost and effectiveness values employed in the budgetary impact analysis and economic evaluation.
| Parameters of the modela | ||
| Concept |
Average value |
|
| Monthly cost of medication (euros) | ||
| Talazoparib | 5413.69€ | |
| Capecitabine | 162.97€ | |
| Eribulin | 2695.50€ | |
| Gemcitabine | 488.10€ | |
| Vinorelbine | 1022.66€ | |
| Cost of adverse events (euros) | ||
| Anemia | 8483.74€ | |
| Neutropenia | 427.26€ | |
| Diarrhoea | 61.53€ | |
| Nausea and vomiting | 56.58€ | |
| Constipation | 58.25€ | |
| Cost of follow-up (euros) | ||
| Follow-up | 111.33€ | |
| Utility values | ||
| Paracha (2016) | ||
| Scenario 1 |
Scenario 2 |
|
| Free | 0.66 | 0.64 |
| After relapse | 0.447 | 0.447 |
| Death | 0 | 0 |
| Ettl (2018) | ||
| Talazoparib | 0.619 (TAD: 24 months) | |
| TSM | 0.609 (TAD:6 months) | |
| Death | 0 | |
a
The cost of pharmaceutical treatment and adverse events includes visits to the specialist; TSM: treatment suggested by the patient’s breast cancer medical doctor. TAD: time to deterioration.